|Bid||67.50 x 0|
|Ask||70.10 x 0|
|Day's Range||69.00 - 71.70|
|52 Week Range||66.70 - 92.80|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 29, 2017|
|1y Target Est||N/A|
Cosmo Pharmaceuticals N.V. (SIX: COPN) ( XETRA: C43) invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius™, the first device approved by the US Food and Drug Administration (FDA) that uses artificial intelligence to help detect potential signs of colon cancer. GI Genius™ is also approved in Europe, Australia, Israel and the United Arab Emirates and is available under an exclusive worldwide distribution agreement with Medtronic.
Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius™ intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy.
Cosmo Pharmaceuticals N.V. (SIX: COPN) reports Full-Year results for the year ended 31 December 2020.